<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190670</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-PK16</org_study_id>
    <nct_id>NCT01190670</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus</brief_title>
  <official_title>A Phase 1, Open Label, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to characterize the effect of multiple doses of ASP015K on the
      pharmacokinetics of a single oral dose or a single intravenous (IV) dose of tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-part study. Part 1 is a 2-sequence, drug interaction study to determine the
      effect of two different ASP015K doses on the pharmacokinetics of oral tacrolimus. Part 2 is a
      1-sequence drug interaction study to determine the effect of the higher dose ASP015K on the
      pharmacokinetics of IV tacrolimus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables assessment through analysis of blood and urine samples</measure>
    <time_frame>Days 1-13 and Days 26-33 (Part 1 only) sampled daily</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of ASP015K and Tacrolimus</condition>
  <arm_group>
    <arm_group_label>Part 1, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K, low dose followed by high dose, with oral tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K, high dose followed by low dose, with oral tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K high dose with intravenous tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Oral and Intravenous</description>
    <arm_group_label>Part 1, Group 1</arm_group_label>
    <arm_group_label>Part 1, Group 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>Oral</description>
    <arm_group_label>Part 1, Group 1</arm_group_label>
    <arm_group_label>Part 1, Group 2</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject weighing at least 45kg and body mass index (BMI) of 18-32 kg/m2, inclusive

          -  If female, subject is at least 2 years post menopausal or is surgically sterile per
             documentation provided by a third party medical professional and the subject is not
             pregnant as documented by a negative serum pregnancy test

          -  If male, subject agrees to sexual abstinence, is surgically sterile, or is using a
             medically acceptable method to prevent pregnancy during the study period

          -  12-lead ECG is normal or if abnormal, the abnormality is not clinically significant

          -  Clinical laboratory test results are within normal limits or not clinically
             significant

          -  Medically healthy, with no clinically significant medical history or abnormalities

        Exclusion Criteria:

          -  History of any clinically significant disorder, disease or malignancy excluding
             non-melanoma skin cancer

          -  Recent history (within 6 months) of drug or alcohol abuse or positive urine screen for
             drugs of abuse/illegal drugs

          -  Treatment with prescription drugs or complementary and alternative medicines (CAM)
             within 14 days prior to study drug administration, or over the counter medication
             within 1 week prior to study drug administration

          -  A symptomatic, viral, bacterial or fungal infection within 1 week prior to clinic
             check-in

          -  Positive test for hepatitis C antibody, or positive test for hepatitis B surface
             antigen (HBsAg)

          -  History of human immunodeficiency virus (HIV) antibody

          -  Positive tuberculosis (TB) skin test or Quantiferon Gold test

          -  Vaccinated within the last 30 days prior to study drug administration

          -  Received an experimental agent within 30 days or five half-lives, whichever is longer,
             prior to study drug administration

          -  Any significant blood loss, donated one unit (450 mL) of blood or more, or received a
             transfusion of any blood or blood products within 60 days or donated plasma within 7
             days prior to clinic admission

          -  Absolute neutrophil count (ANC) &lt;2500 cells/mm3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>October 12, 2010</last_update_submitted>
  <last_update_submitted_qc>October 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr Manager Clinical Trials Registry</name_title>
    <organization>Astellas Pharma Global Development</organization>
  </responsible_party>
  <keyword>ASP015K</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

